Bio-Techne (NASDAQ:TECH) vs. Seer (NASDAQ:SEER) Critical Contrast

Bio-Techne (NASDAQ:TECH) and Seer (NASDAQ:SEER) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Profitability

This table compares Bio-Techne and Seer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Seer	-478.05%	-27.23%	-23.99%

Volatility and Risk

Bio-Techne has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.

Valuation & Earnings

This table compares Bio-Techne and Seer”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22 billion	9.35	$181.86 million	$1.15	63.00
Seer	$16.58 million	6.48	-$73.60 million	($1.22)	-1.59

Bio-Techne has higher revenue and earnings than Seer. Seer is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Bio-Techne and Seer, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0	15	2	0	2.12
Seer	1	0	0	2	3.00

Bio-Techne presently has a consensus target price of $68.92, indicating a potential downside of 4.87%. Seer has a consensus target price of $4.00, indicating a potential upside of 106.19%. Given Seer’s stronger consensus rating and higher possible upside, analysts plainly believe Seer is more favorable than Bio-Techne.

Insider & Institutional Ownership

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 75.2% of Seer shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 11.3% of Seer shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Bio-Techne beats Seer on 10 of the 15 factors compared between the two stocks.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.